Latest Content

Round on the latest news in psychiatry from the last week.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

A psychiatrist and psychiatric nurse practitioner discuss collaboration and patient support.

Check out the pipeline updates from April!

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

Clinicians explore neuroscience-guided off-label prescribing.

DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.